Detail akcie Vanda Pharma online

Business Summary: Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Vanda Pharmaceuticals Inc. revenues decreased 24% to $192.6M. Net income decreased 60% to $2.5M. Revenues reflect Hetlioz segment decrease of 37% to $100.2M, Fanapt segment decrease of 4% to $90.9M. Net income also reflects Intangible asset amortization increase of 38% to $2.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $0.11 to $0.04.